Quantitative Sensory Testing (QST) - Does assessing ... - TI Pharma

More documents

Recommendations

Info

3. Somatosensory function and neuropathic pain grading 2.5.4. Correlation between background pain and neuropathic pain grades To identify a possible relationship between neuropathic pain grade and background pain of each patient, Pearson correlation was used. P-values
3. Somatosensory function and neuropathic pain grading Out of the total of 418 different body areas that were tested across all healthy controls 62% (259 locations) showed normal sensory function and 38% (159 locations) showed a sensory abnormality for at least one QST parameter. Sensory abnormalities were regarded as sensory gain in 21%, sensory loss in 13% and a mixture of sensory gain and sensory loss in 4% of the cases (Fig.3-1). 3.2. Demographics of patients Demographic data of the patients are shown in Table 3-1. Apart from two patients, all patients reported ongoing spontaneous pain ranging from 3 to 100 (Mean 63.2 ± 22.8 SD) on a 0-100 NRS just before the QST assessment took place. 3.2.1. Clinical diagnose of neuropathic pain The aetiology of patient’s pain in our sample was diverse. The largest subgroup developed pain after a surgical intervention (33) followed by patients who had a trauma (18). Other causes of pain were polyneuropathy (12), failed back surgery (10), pain after fracture (7), Herniated Nucleus Pulposus (HNP) (6), spinal cord injury (4), peripheral nerve entrapment (4), central pain (3), amputation (3), Herpes Zoster infection (3), Radiotherapy (3), and pain after infection (2). The clinical diagnoses of patients included peripheral nerve injury (83), polyneuropathy (14), spinal cord injury (4), central pain (3), postherpetic neuralgia (3) and complex regional pain syndrome (CRPS) (1) (see Table 3-1).
Page 2:
Quantitative Sensory Testing (QST)
Page 5 and 6: Promotores: Prof. dr. M.M.R.F. Stru
Page 7 and 8: Paranimfen Marten Harbers Aribert B
Page 9 and 10: Contents 3.3.4. Sensory changes at
Page 11: 0 Contents Chapter 5 Do patients wi
Page 14: Chapter 1 General introduction
Page 17 and 18: 1. General introduction stimuli. C-
Page 19 and 20: 1. General introduction Patients re
Page 21 and 22: 1. General introduction 0 drugs (NS
Page 23 and 24: 1. General introduction Table 1-2:
Page 26 and 27: Chapter 2 Bilateral sensory abnorma
Page 28 and 29: 2. Bilateral abnormalities in neuro
Page 46: 2. Bilateral abnormalities in neuro
Page 49 and 50: 3. Somatosensory function and neuro
Page 51 and 52: 0 3. Somatosensory function and neu
Page 53: 3. Somatosensory function and neuro
Page 67 and 68: 4. QST and neuropathic pain mechani
Page 81 and 82: 5. QST in patients with tendinopath
Page 94 and 95: Chapter 6 General discussion and Su
Page 96 and 97: 6. General discussion and Summary s
Page 98 and 99: 6. General discussion and Summary s
Page 100 and 101: 6. General discussion and Summary T
Page 102 and 103: 6. General discussion and Summary Q
Page 104 and 105:
6. General discussion and Summary S
Page 106 and 107:
References Abate M, Silbernagel KG,
Page 108 and 109:
de la Llave-Rincon AI, Fernandez-de
Page 110 and 111:
Kehlet H, Jensen TS, Woolf CJ. 2006
Page 112 and 113:
Robinson JM, Cook JL, Purdam C, Vis
Page 114 and 115:
Visentini PJ, Khan KM, Cook JL, Kis
Page 116 and 117:
Nederlandse samenvatting Met de ont
Page 118 and 119:
Acknowledgement To produce a work s
show all

Quantitative Sensory Testing (QST) - Does assessing ... - TI Pharma

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?